Dr Reddy's Laboratories, the country's second biggest drug maker, revealed an unexpected consolidated net loss of Rs 522 crore in the October-December quarter, due to a writedown of intangible assets and goodwill in its German arm, Betapharm.
Dr Reddys Laboratories surged in early trades on Friday on good buying support, but it slipped from the days high. The scrip of the local pharmaceutical major continued to witness volatility.
Dr Reddy's Laboratories plans to brand its speciality drugs sold in the US. It will begin selling branded skin care products by year-end. The venture will be spearheaded by Promius Pharma, a wholly owned subsidiary of its US arm
The $66 million (Rs 272.8 crore) Leiner Health Products is likely to sue DRL for the early divorce (the agreement has lasted only four years) from the alliance.
Pharmaceutical major Dr Reddy's Laboratories Ltd on Tuesday said it will offer up to 13.5 million American Depositary Shares.
Global drug maker Dr Reddy's Laboratories is adding 1,300 people this year, including about 350 through campus recruitment, according to Prabir Kumar Jha, DRL's senior vice-president and global chief.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
Dr Reddy's Laboratories Limited aims to increase the R&D spend on its three major research programmes, including the reverse cholesterol transport area, in a bid to come out with pathbreaking molecules in the next 7-10 years.
Equity market investors would track global trends, foreign fund movement and quarterly earnings in a holiday-shortened week ahead, analysts said. Stock exchanges BSE and NSE will conduct a special Muhurat trading session on Tuesday, October 21.
Indian drug maker Dr Reddy's Laboratories said on Friday its fiscal 2003 profit fell 28 per cent, on lower sales of a Prozac generic drug to the key US market and slowing domestic sales.\n\n\n\n
After sealing the area of the nitrogen gas leak that left two persons dead, Dr Reddy's Laboratories (DRL) is to be served a notice on the incident that occured at its manufacturing plant at Bollaram on the outskirts of Hyderabad.
The list, posted on a website link launched by the US regulator, includes ABB, HSBC, Nokia, Unilever, Cadbury, Total and Siemens among others.
Dr Reddy's Laboratories Ltd expects the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period, a senior official of the city-based drug maker said.
Dr Reddy's Laboratories, the second largest drug maker in the country, would invest about Rs 750 crore.
Indian drugmaker Dr Reddy's Laboratories said on Thursday it had filed an application with the US Food and Drug Administration to market a generic form of GlaxoSmithKline's anti-nausea drug Zofran.\n\n
Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.
A three-member committee, comprising two officials from the Director of Factories and one pharma expert, will probe the gas leak at a production unit of Dr Reddy's Laboratories (DRL). The Director of Factories will appoint a pharma domain expert soon.
Dr Reddys Laboratories Ltd has posted a net profit of Rs 931.60 million for the quarter ended December 31, 2002 as compared to a net profit of Rs 1615.30 million in the quarter ended December 31,2001.
Dr Reddy's has offered a price of 0.52 euro in cash for each OctoPlus share.
The plant and associated facilities focus on manufacturing or packaging Amoxicilin-based products, which include semi-synthetic penicillin
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
In addition, the CPSC asserted that the company violated the CPSA by failing to immediately advise the CPSC of the alleged violations.
Dr Reddy's Laboratories (DRL) is set to acquire Haleon's global portfolio of consumer healthcare brands in the nicotine replacement therapy (NRT) category outside of the US. DRL will pay a total consideration of 500 million, including an upfront cash consideration of 458 million and contingent cash payments up to 42 million based on performances in CY25 and CY26. DRL will acquire the portfolio through the purchase of shares of Northstar Switzerland SARL, a Haleon group firm.
Take the Rediff Biz Quiz and find out how much you know about India Inc's merger and acquisition operatiosns.
The US drug regulator raised the issue of significant deviations from the current good manufacturing practice (cGMP) in three of DRRD's plants in a letter issued in November 2015
A new logo, colour and tagline were unveiled last month.
DRL launched four new products in North America during the previous quarter.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
Pfizer Inc and its group companies filed a petition in a US court against Aurobindo Pharma Ltd and Dr Reddy's Laboratories alleging that the Indian drug-makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent.
Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.
Suit alleges fraud by hiding significant deficiencies in CGMP regulations enforced by US health regulator.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
Dr Reddy's gets warning from US health regulator
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
Analysts are eyeing bigger launches that will positively impact company's fortunes.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
I would like to renew our commitment to advancing the frontiers of science in drug discovery, says the chairman of Dr Reddy's Labs.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances